FDA Panel Set to Review GRAIL Multi-Cancer Blood Test
A blood test designed to detect signals from multiple types of cancer is heading toward a major U.S. regulatory review, with a Food and Drug Administration advisory panel scheduled to examine GRAIL’s Galleri test later this month.
What Galleri Is Designed to Do
Galleri is a blood-based multi-cancer early detection test intended to identify molecular signals associated with cancer. The test analyzes patterns in cell-free DNA and is designed to detect signals from more than 50 types of cancer from a single blood sample.
If a cancer signal is detected, the test can estimate where in the body the signal originated. That information is intended to help guide follow-up diagnostic evaluation rather than serve as a stand-alone cancer diagnosis.
FDA Review Is Scheduled for September 23
The FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to review GRAIL’s premarket approval application on September 23, 2026. The panel will discuss evidence and make recommendations, although the FDA is not required to follow an advisory committee vote.
The review represents an important regulatory step because premarket approval is among the FDA’s most stringent pathways for medical devices.
Why Early Detection Is Difficult
Many cancers are easier to treat when found at an earlier stage, but existing screening programs cover only a limited number of cancer types. A blood test capable of identifying signals from multiple cancers could potentially complement established screening programs.
However, detecting a molecular signal is not the same as proving that screening improves survival. A positive result can lead to additional scans, procedures and biopsies, while a false-negative result could create false reassurance.
Evidence Remains Important
Reuters reported that a three-year U.K. trial of Galleri did not significantly increase early cancer detection or reduce late-stage diagnoses. Those findings are part of the broader evidence environment surrounding the test.
Regulators and medical professionals therefore face questions about the balance between potential benefits, false results, follow-up procedures, cost and the effect of screening on patient outcomes.
Not a Replacement for Standard Screening
Multi-cancer detection tests are generally discussed as additions to, rather than replacements for, established screening recommendations. Depending on age and risk, patients may still need mammograms, colorectal cancer screening, cervical cancer screening, lung cancer screening or other evidence-based tests.
A positive result from a blood test also requires clinical follow-up before cancer can be diagnosed.
What the Advisory Review Could Clarify
The September meeting could provide insight into how experts assess the available evidence and what conditions may be necessary if the test receives regulatory approval.
For patients, the central issue will remain whether using the test improves meaningful health outcomes. Regulatory review is designed to examine that evidence rather than simply evaluate whether a technology is technically capable of detecting biological signals.
Related Hudson Tribune coverage: New FDA treatment approval.
Source: Reuters; FDA Medical Devices Advisory Committee.
